Document is current
Any future updates will be listed below
-
Authors
Sun, Mingyuan
Jing, Hongmei
Qu, Xiaoyan
Dong, Fei
Li, Yi
Feng, Zhaoyi
Ziti-Ljajic, Samira
Semiond, Dorothee
Li, Lingyu
Qi, Junyuan
Qiu, Lugui
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03733717 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
https://doi.org/10.1038/s41598-024-59186-1
-
Funding
Funding for this research was provided by:
Sanofi (N. A.)
Sanofi (N. A.)
Sanofi (N. A.)
Sanofi (N. A.)
Sanofi (N. A.)
- License Information
-
More Information
Article History
Received: 11 July 2023
Accepted: 8 April 2024
First Online: 11 November 2024
Competing interests
: MS, HJ, XQ, FD, and JQ: nothing to disclose. YL, ZF, SZ-L, DS, and LL are employed by Sanofi and may hold stock and/or stock options. LQ: consulting for AstraZeneca, Beigene, Xi'an Janssen, Pfizer; Speaker Bureau participation for AstraZeneca, Beigene, Xi'an Janssen, Pfizer, Roche, and Sanofi.
